These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38667795)

  • 41. Itraconazole interferes in the pharmacokinetics of fuzuloparib in healthy volunteers.
    Hu C; Zhang Y; Pei T; Liu P; Zhang L
    Cancer Chemother Pharmacol; 2023 Jun; 91(6):523-529. PubMed ID: 37166499
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.
    Poggesi I; Li LY; Jiao J; Hellemans P; Rasschaert F; de Zwart L; Snoeys J; De Meulder M; Mamidi RNVS; Ouellet D
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):101-111. PubMed ID: 31673875
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.
    Kubo M; Koue T; Inaba A; Takeda H; Maune H; Fukuda T; Azuma J
    Drug Metab Pharmacokinet; 2005 Feb; 20(1):55-64. PubMed ID: 15770075
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healthy Chinese subjects.
    Cao B; Huang L; Liu M; Lin H; Ma T; Zhao Y; Geng Y; Yang Y; Guo H; Li J
    Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):653-664. PubMed ID: 37811634
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Influence of grapefruit juice on the systemic availability of itraconazole oral solution in healthy adult volunteers.
    Gubbins PO; McConnell SA; Gurley BJ; Fincher TK; Franks AM; Williams DK; Penzak SR; Saccente M
    Pharmacotherapy; 2004 Apr; 24(4):460-7. PubMed ID: 15098799
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib.
    Malhi V; Colburn D; Williams SJ; Hop CE; Dresser MJ; Chandra P; Graham RA
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):41-9. PubMed ID: 27154174
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data.
    Templeton I; Peng CC; Thummel KE; Davis C; Kunze KL; Isoherranen N
    Clin Pharmacol Ther; 2010 Oct; 88(4):499-505. PubMed ID: 20739919
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Open-Label Assessment of the Effects of Itraconazole and Rifampicin on Balovaptan Pharmacokinetics in Healthy Volunteers.
    Derks MGM; Wandel C; Young A; Bolt SK; Meyenberg C
    Adv Ther; 2020 Nov; 37(11):4720-4729. PubMed ID: 32935287
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.
    Zahir H; Greenberg J; Shuster D; Hsu C; Watanabe K; LaCreta F
    Clin Pharmacokinet; 2022 Nov; 61(11):1623-1639. PubMed ID: 36264536
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.
    Nemunaitis J; Young A; Ejadi S; Miller W; Chen LC; Nichols G; Blotner S; Vazvaei F; Zhi J; Razak A
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):529-537. PubMed ID: 29368050
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions.
    Prieto Garcia L; Janzén D; Kanebratt KP; Ericsson H; Lennernäs H; Lundahl A
    Drug Metab Dispos; 2018 Oct; 46(10):1420-1433. PubMed ID: 30068519
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of Strong Inhibition of Cytochrome P450 3A and UDP glucuronosyltransferase 1A9 and Strong Induction of Cytochrome P450 3A on the Pharmacokinetics, Safety, and Tolerability of Soticlestat: Two Drug-Drug Interaction Studies in Healthy Volunteers.
    Yin W; Dong C; Stevenson A; Lloyd V; Petrillo M; Baratta M; Hui T; Han S
    Drug Metab Dispos; 2024 Feb; 52(3):180-187. PubMed ID: 38123352
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Phase 1, Open-Label Study to Evaluate the Effect of Food and Concomitant Itraconazole Administration on the Pharmacokinetics of AMG 986 in Healthy Subjects.
    Trivedi A; Mather O; Vega S; Hutton S; Hellawell J; Lee E
    Clin Pharmacol Drug Dev; 2022 Jul; 11(7):849-856. PubMed ID: 35247290
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel.
    Sarantopoulos J; Mita AC; Wade JL; Morris JC; Rixe O; Mita MM; Dedieu JF; Wack C; Kassalow L; Lockhart AC
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1113-24. PubMed ID: 25307552
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer.
    Molenaar-Kuijsten L; Braal CL; Groenland SL; de Vries N; Rosing H; Beijnen JH; Koolen SLW; Vulink AJE; van Dongen MGJ; Mathijssen RHJ; Huitema ADR; Steeghs N;
    Clin Pharmacol Ther; 2022 Feb; 111(2):477-484. PubMed ID: 34674222
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite.
    Li J; Kankam M; Trone D; Gammon G
    Br J Clin Pharmacol; 2019 Sep; 85(9):2108-2117. PubMed ID: 31173645
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Open-Label Crossover Oral Bioequivalence Pharmacokinetics Comparison for a 3-Day Loading Dose Regimen and 15-Day Steady-State Administration of SUBA-Itraconazole and Conventional Itraconazole Capsules in Healthy Adults.
    Thompson GR; Lewis P; Mudge S; Patterson TF; Burnett BP
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32457106
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.
    Cruz C; Llop-Guevara A; Garber JE; Arun BK; Pérez Fidalgo JA; Lluch A; Telli ML; Fernández C; Kahatt C; Galmarini CM; Soto-Matos A; Alfaro V; Pérez de la Haza A; Domchek SM; Antolin S; Vahdat L; Tung NM; Lopez R; Arribas J; Vivancos A; Baselga J; Serra V; Balmaña J; Isakoff SJ
    J Clin Oncol; 2018 Nov; 36(31):3134-3143. PubMed ID: 30240327
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An Adaptive Physiologically Based Pharmacokinetic-Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers.
    Riddell K; Patel A; Collins G; Zhou Y; Schramek D; Kremer BE; Ferron-Brady G
    J Clin Pharmacol; 2021 Jan; 61(1):125-137. PubMed ID: 32820548
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potential Drug-Drug Interactions with Combination Volasertib + Itraconazole: A Phase I, Fixed-sequence Study in Patients with Solid Tumors.
    Lang I; Liu D; Fritsch H; Taube T; Chizhikov E; Liptai B
    Clin Ther; 2020 Nov; 42(11):2214-2224. PubMed ID: 33139055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.